financetom
Business
financetom
/
Business
/
Market Chatter: MetLife in Talks to Acquire Non-China Assets of PineBridge
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Market Chatter: MetLife in Talks to Acquire Non-China Assets of PineBridge
Oct 21, 2024 3:14 AM

05:55 AM EDT, 10/21/2024 (MT Newswires) -- MetLife ( MET ) is in talks to buy PineBridge Investments' non-China assets in a deal that could be valued at $1 billion to $1.5 billion, Bloomberg reported on Monday, citing unnamed people familiar with the matter.

The talks for assets under management totaling about $100 billion, Bloomberg reported.

MetLife ( MET ) has outbid other companies seeking to buy the assets and has entered into an exclusivity period allowing it to fine tune its offer, the report said.

PineBridge, which is majority-owned by Hong Kong businessman Richard Li's Pacific Century Group, has been seeking to sell all but its China assets, which are part of a joint venture with Huatai Securities, the report said.

MetLife ( MET ) and PineBridge did not immediately reply to MT Newswires' requests for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 85.84, Change: +0.52, Percent Change: +0.61

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Vertex Pharma lifts annual revenue forecast on cystic fibrosis treatments strength
Vertex Pharma lifts annual revenue forecast on cystic fibrosis treatments strength
Nov 4, 2024
Nov 4 (Reuters) - Vertex Pharmaceuticals ( VRTX ) raised its annual revenue forecast on Monday after it beat third-quarter estimates on demand for its cystic fibrosis (CF) treatments. The drugmaker now expects 2024 product revenue between $10.8 billion and $10.9 billion compared to its prior expectations of $10.65 billion to $10.85 billion. Analysts expect annual revenue of $10.75 billion,...
Vertex Pharma lifts annual revenue forecast on cystic fibrosis treatments strength
Vertex Pharma lifts annual revenue forecast on cystic fibrosis treatments strength
Nov 4, 2024
(Reuters) - Vertex Pharmaceuticals ( VRTX ) raised its annual revenue forecast on Monday after it beat third-quarter estimates on demand for its cystic fibrosis (CF) treatments. The drugmaker now expects 2024 product revenue between $10.8 billion and $10.9 billion compared to its prior expectations of $10.65 billion to $10.85 billion. Analysts expect annual revenue of $10.75 billion, according to...
--Vertex Pharmaceuticals Raises Full Year 2024 Product Revenue Guidance to $10.8-$10.9 Billion, vs Prior View of $10.65-$10.85 Billion
--Vertex Pharmaceuticals Raises Full Year 2024 Product Revenue Guidance to $10.8-$10.9 Billion, vs Prior View of $10.65-$10.85 Billion
Nov 4, 2024
04:03 PM EST, 11/04/2024 (MT Newswires) -- Price: 468.00, Change: -3.12, Percent Change: -0.66 ...
Diamondback Energy misses estimates for third-quarter profit
Diamondback Energy misses estimates for third-quarter profit
Nov 4, 2024
Nov 4 (Reuters) - Diamondback Energy ( FANG ) missed estimates for third-quarter profit on Monday as the oil and gas firm was hurt by lower prices. The company reported an adjusted profit of $3.38 per share for the quarter ended Sept. 30, compared with analysts' average estimate of $3.98 per share, according to data compiled by LSEG. (Reporting by...
Copyright 2023-2026 - www.financetom.com All Rights Reserved